AR and prostate cancer: (10R,11R) Derivatives 8A and 41A cannot suppress 22Rv1 prostate cancer cell proliferation up to 10 μM concentration, suggesting that they are very likely binding to the ligand-binding domain on AR to exhibit antiproliferative activity in LNCaP cells.